

Quality ID #489 (CBE 1662): Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy

2026 COLLECTION TYPE:

MERIT-BASED INCENTIVE PAYMENT SYSTEM (MIPS) CLINICAL QUALITY MEASURE (CQM)

MEASURE TYPE:

Process

DESCRIPTION:

Percentage of patients aged 18 years and older with a diagnosis of chronic kidney disease (CKD) (Stages 1-5, not receiving Renal Replacement Therapy (RRT)) and proteinuria who were prescribed ACE inhibitor or ARB therapy within a 12-month period.

INSTRUCTIONS:

Reporting Frequency:

This measure is to be submitted a minimum of once per performance period for denominator eligible cases as defined in the denominator criteria.

Intent and Clinician Applicability:

This measure is intended to reflect the quality of services provided for patients with a diagnosis of CKD (Stages 1-5, not receiving Renal Replacement Therapy (RRT)) and proteinuria seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions as defined by the numerator based on the services provided and the measure-specific denominator coding.

Measure Strata and Performance Rates:

This measure contains one strata defined by a single submission criteria.

This measure produces a single performance rate.

Implementation Considerations:

For the purposes of MIPS implementation, this patient-process measure is submitted a minimum of once per patient for the performance period. The most advantageous quality data code (QDC) will be used if the measure is submitted more than once.

Telehealth:

TELEHEALTH ELIGIBLE: This measure is appropriate for and applicable to the telehealth setting. Patient encounters conducted via telehealth using encounter code(s) found in the denominator encounter criteria are allowed for this measure. Therefore, if the patient meets all denominator criteria for a telehealth encounter, it would be appropriate to include them in the denominator eligible patient population. Telehealth eligibility is at the measure level for inclusion within the denominator eligible patient population and based on the measure specification definitions which are independent of changes to coding and/or billing practices.

Measure Submission:

The quality data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this collection type for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. The coding provided to identify the measure criteria: Denominator or Numerator, may be an example of coding that could be used to identify patients that meet the intent of this clinical topic. When implementing this measure, please refer to the 'Reference Coding' section to determine if other codes or code languages that meet the intent of the criteria may also be used within the medical record to identify and/or assess patients. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

DENOMINATOR:

All patients aged 18 years and older with the diagnosis of CKD (Stages 1-5, not receiving RRT) and proteinuria.

Definitions:

Proteinuria –

1. > 300mg of albumin in the urine per 24 hours OR
2. Urine albumin-to-creatinine ratio (ACR) > 300 mg/g OR
3. Urine protein-to-creatinine ratio (PCR) > 0.3 g/g

Renal Replacement Therapy (RRT) – For the purposes of this measure, RRT includes hemodialysis, peritoneal dialysis, and kidney transplantation.

Patients receiving RRT – see **Reference Coding**

Denominator Criteria (Eligible Cases):

All patients aged 18 years and older on the date of the encounter

AND

Diagnosis of CKD (Stages 1-5) (ICD-10-CM): E11.22, N18.1, N18.2, N18.30, N18.31, N18.32, N18.4, N18.5, N18.9

AND

Diagnosis of Proteinuria (ICD-10-CM): R80.1, R80.8, R80.9

AND

Patient encounter during the performance period (CPT): 98000, 98001, 98002, 98003, 98004, 98005, 98006, 98007, 98008, 98009, 98010, 98011, 98012, 98013, 98014, 98015, 98016, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99341, 99342, 99344, 99345, 99347, 99348, 99349, 99350

AND NOT

DENOMINATOR EXCLUSION:

Patients receiving RRT: M1199

Reference Coding:

Denominator Exclusion for **RRT [M1199]** is defined by the following coding **only**: 90951, 90952, 90953, 90954, 90955, 90956, 90957, 90958, 90959, 90960, 90961, 90962, 90963, 90964, 90965, 90966, 90967, 90968, 90969, 90970, I70.1, N18.6, Z49.31, Z49.32, Z99.2

NUMERATOR:

Patients who were prescribed ACE inhibitor or ARB therapy within a 12-month period.

Definition:

Prescribed – May include prescription given to the patient for ACE Inhibitor or ARB therapy OR patient already taking ACE Inhibitor or ARB therapy as documented in the current medication list.

Numerator Options:

Performance Met:

ACE Inhibitor (ACE-I) or ARB therapy prescribed during the measurement period (**M1200**)

OR

Denominator Exception:

Documentation of medical reason(s) for not prescribing ACE inhibitor (ACE-I) or ARB therapy during the measurement period (e.g., pregnancy, history of angioedema to ACE-I, other allergy to ACE-I and ARB, hyperkalemia or history of hyperkalemia while on ACE-I or ARB therapy, acute kidney injury due to ACE-I or ARB therapy, other medical reasons.) (**M1201**)

OR

Denominator Exception:

Documentation of patient reason(s) for not prescribing ACE inhibitor or ARB therapy during the measurement period (e.g., patient declined, other patient reasons) (M1202)

OR

Performance Not Met:

ACE inhibitor or ARB therapy not prescribed during the measurement period, reason not given (M1203)

RATIONALE:

This measure is aimed at increasing the number of patients with CKD and proteinuria who are prescribed ACE inhibitor or ARB therapy. ACE inhibitors and ARBs are preferred agents for diabetic kidney disease and nondiabetic kidney diseases with proteinuria (albuminuria), even in the absence of hypertension. In these diseases, ACE inhibitors and ARBs lower blood pressure, reduce proteinuria (albuminuria), slow the progression of kidney disease, and likely reduce cardiovascular disease risk by mechanisms in addition to lowering blood pressure. These benefits have been shown across high quality, multi-center, randomized controlled trials such as RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (Brenner et al., New England Journal of Medicine, 2001). A meta-analysis of randomized trials showed that ACEi/ARB therapy lowered the odds of kidney failure (also known as end-stage renal disease [ESRD]) by 30-39 percent and of cardiovascular disease events by 18 percent-24 percent (Xie et al., Am J Kidney Dis, 2016). In a meta-analysis including primarily diabetic patients with proteinuria, use of ACEi/ARB therapy had a 0.36 to 0.78 odds of incident kidney failure (Cai et al., Nephrology, dialysis, transplantation, 2018). Similarly, in a Cochrane meta-analysis, patients with early (stage 1 to 3) non-diabetic CKD who were treated versus not treated with ACEi/ARB had 31 percent lower risk of kidney failure (Jafar et al., Annals of internal medicine, 2001). Based upon this robust evidence, ACE inhibitors and ARBs are recommended for patients with CKD and proteinuria by the Kidney Disease: Improving Global Outcomes (KDIGO) international guidelines and the Kidney Disease Outcomes Quality Initiative.

CKD is a major public health problem; a total of 37 million Americans have CKD. There is a clear performance gap in ACE inhibitor and ARB usage among patients with CKD, with only 40 percent of CKD patients receiving an ACEi/ARB in NHANES data (Murphy et al., JASN, 2019). Population health efforts to increase the use of ACEi/ARB in American Indians and Alaska Natives have been associated with a decrease in incident kidney failure related to diabetic kidney disease (Bullock et al., MMWR Morbidity and mortality weekly report, 2017). In summary, this measure is a central component of high-quality nephrology care, as ACE inhibitors and ARBs decrease the rate of kidney failure, cardiovascular outcomes, and mortality in patients with CKD and proteinuria.

CLINICAL RECOMMENDATION STATEMENTS:

Clinical practice guidelines support the use of ACE and ARB in CKD patients not on RRT.

The Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines for the evaluation and management of CKD recommend that "an ARB or ACE-I be used in both diabetic and non-diabetic adults with CKD and urine albumin excretion > 300 mg/24 hours (or equivalent)" (Recommendation 3.1.7, 1B). Guideline available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.

The KDIGO 2021 Clinical Practice Guideline on the Management of Blood Pressure (BP) in CKD recommends "starting renin-angiotensin-system inhibitors (RASi) (ACEi or ARB) for people with high BP, CKD, and severely increased albuminuria (G1–G4, A3) without diabetes" and "for people with high BP, CKD, and moderately-to-severely increased albuminuria (G1–G4, A2 and A3) with diabetes" (Recommendations 3.2.1 and 3.2.3, 1B). Guideline available at <https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2021-BP-GL.pdf>.

This measure was rated as HIGH for Overall Measure Validity in Mendum ML, Tummalaapalli SL, Lentine KL, Erickson KF, Lew SQ, Liu F, Gould E, Somers M, Garimella PS, O'Neil T, White DL, Meyer R, Bieber SD, Weiner DE. *Measuring Quality in Kidney Care: An Evaluation of Existing Quality Metrics and Approach to Facilitating Improvements in Care Delivery*. J Am Soc Nephrol. 2020 Mar;31(3):602-614. doi: 10.1681/ASN.2019090869. Epub 2020 Feb 13. PMID: 32054692; PMCID: PMC7062216.

REFERENCES:

The Kidney Disease Improving Global Outcomes (KDIGO) 2012 (Recommendation 3.1.7, 1B). Guideline available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.

The KDIGO 2021 Clinical Practice Guideline on the Management of Blood Pressure (BP) in CKD (Recommendations 3.2.1 and 3.2.3, 1B). Guideline available at <https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2021-BP-GL.pdf>.

Mendu ML, TummalaPalli SL, Lentine KL, Erickson KF, Lew SQ, Liu F, Gould E, Somers M, Garimella PS, O'Neil T, White DL, Meyer R, Bieber SD, Weiner DE. *Measuring Quality in Kidney Care: An Evaluation of Existing Quality Metrics and Approach to Facilitating Improvements in Care Delivery*. J Am Soc Nephrol. 2020 Mar;31(3):602-614. doi: 10.1681/ASN.2019090869. Epub 2020 Feb 13. PMID: 32054692; PMCID: PMC7062216.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.

Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis. 2016 May;67(5):728-41. doi: 10.1053/j.ajkd.2015.10.011. Epub 2015 Nov 18. PMID: 26597926.

Cai J, Huang X, Zheng Z, Lin Q, Peng M, Shen D. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis. Nephrol Dial Transplant. 2018; 33(11):1968-1976. doi: 10.1093/ndt/gfy001

Jafar TH, Schmid CH, Landa M, et al. Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data. Ann Intern Med. 2001;135:73-87. [Epub 17 July 2001]. doi:10.7326/0003-4819-135-2-200107170-00007

Murphy DP, Drawz PE, Foley RN. Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States. J Am Soc Nephrol. 2019 Jul;30(7):1314-1321. doi: 10.1681/ASN.2018100971.

Bullock A, Burrows NR, Narva AS, et al. Vital Signs: Decrease in Incidence of Diabetes-Related End-Stage Renal Disease among American Indians/Alaska Natives — United States, 1996–2013. MMWR Morb Mortal Wkly Rep 2017;66:26-32. DOI: 10.15585/mmwr.mm6601e1.

COPYRIGHT:

© 2011-2026 Renal Physicians Association. All rights reserved.

The measure is not a clinical guideline, does not establish a standard of medical care, and has not been tested for all potential applications.

The measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg. use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the measure for commercial gain, or incorporation of the measure into a product or service that is sold, licensed or distributed for commercial gain.

THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. ©


CPT® contained in the Measure specifications is copyright 2004-2026.

American Medical Association. LOINC® copyright 2004-2026 Regenstrief Institute, Inc.

This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2026 International Health Terminology Standards Development Organisation.
ICD-10 is copyright 2024 World Health Organization. All Rights Reserved.

**2026 Clinical Quality Measure Flow for Quality ID #489 (CBE 1662):
Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy**

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.



SAMPLE CALCULATIONS

Data Completeness=

$$\frac{\text{Performance Met (a=40 patients)} + \text{Denominator Exception (b}^1+\text{b}^2=10 \text{ patients)} + \text{Performance Not Met (c=20 patients)}}{\text{Eligible Population / Denominator (d=80 patients)}} = \frac{70 \text{ patients}}{80 \text{ patients}} = 87.50\%$$

Performance Rate=

$$\frac{\text{Performance Met (a=40 patients)}}{\text{Data Completeness Numerator (70 patients)} - \text{Denominator Exception (b}^1+\text{b}^2=10 \text{ patients)}} = \frac{40 \text{ patients}}{60 \text{ patients}} = 66.67\%$$

*See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process

CPT only copyright 2025 American Medical Association. All rights reserved.

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

v10

2026 Clinical Quality Measure Flow Narrative for Quality ID #489 (CBE 1662):
Adult Kidney Disease: Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor
Blocker (ARB) Therapy

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.

1. Start with Denominator
2. Check *All patients aged 18 years and older on the date of the encounter*:
 - a. If *All patients aged 18 years and older on the date of the encounter* equals No, do not include in *Eligible Population/Denominator*. Stop processing.
 - b. If *All patients aged 18 years and older on the date of encounter* equals Yes, proceed to check *Diagnosis of CKD (Stages 1-5) as listed in Denominator**.
3. Check *Diagnosis of CKD (Stages 1-5) as listed in Denominator**:
 - a. If *Diagnosis of CKD (Stages 1-5) as listed in Denominator** equals No, do not include in *Eligible Population/Denominator*. Stop processing.
 - b. If *Diagnosis of CKD (Stages 1-5) as listed in Denominator** equals Yes, proceed to check *Diagnosis of Proteinuria*.
4. Check *Diagnosis of Proteinuria*:
 - a. If *Diagnosis of Proteinuria* equals No, do not include in *Eligible Population/Denominator*. Stop processing.
 - b. If *Diagnosis of Proteinuria* equals Yes, proceed to check *Patient encounter during the performance period as listed in Denominator**.
5. Check *Patient encounter during the performance period as listed in Denominator**:
 - a. If *Patient encounter during the performance period as listed in Denominator** equals No, do not include in *Eligible Population/Denominator*. Stop processing.
 - b. If *Patient encounter during the performance period as listed in Denominator** equals Yes, proceed to check *Patients receiving RRT*.
6. Check *Patients receiving RRT*:
 - a. If *Patients receiving RRT* equals Yes, do not include in *Eligible Population/Denominator*. Stop processing.
 - b. If *Patients receiving RRT* equals No, include in *Eligible Population/Denominator*.
7. Denominator Population:
 - Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.
8. Start Numerator
9. Check *ACE Inhibitor (ACE-I) or ARB therapy prescribed during the measurement period*:

- a. If *ACE Inhibitor (ACE-I) or ARB therapy prescribed during the measurement period* equals Yes, include in *Data Completeness Met and Performance Met*.
 - *Data Completeness Met and Performance Met* letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in the Sample Calculation.
- b. If *ACE Inhibitor (ACE-I) or ARB therapy prescribed during the measurement period* equals No, proceed to check *Documentation of medical reason(s) for not prescribing ACE inhibitor (ACE-I) or ARB therapy during the measurement period*.

10. Check *Documentation of medical reason(s) for not prescribing ACE inhibitor (ACE-I) or ARB therapy during the measurement period*.

- a. If *Documentation of medical reason(s) for not prescribing ACE inhibitor (ACE-I) or ARB therapy during the measurement period* equals Yes, include in *Data Completeness Met and Denominator Exception*.
 - *Data Completeness Met and Denominator Exception* letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b¹ equals 10 patients in the Sample Calculation.
- b. If *Documentation of medical reason(s) for not prescribing ACE inhibitor (ACE-I) or ARB therapy during the measurement period* equals No, proceed to check *Documentation of patient reason(s) for not prescribing ACE inhibitor or ARB therapy during the measurement period*.

11. Check *Documentation of patient reason(s) for not prescribing ACE inhibitor or ARB therapy during the measurement period*.

- a. If *Documentation of patient reason(s) for not prescribing ACE inhibitor or ARB therapy during the measurement period* equals Yes, include in *Data Completeness Met and Denominator Exception*.
 - *Data Completeness Met and Denominator Exception* letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b² equals 0 patients in the Sample Calculation.
- b. If *Documentation of patient reason(s) for not prescribing ACE inhibitor or ARB therapy during the measurement period* equals No, proceed to check *ACE inhibitor or ARB therapy not prescribed during the measurement period, reason not given*.

12. Check *ACE inhibitor or ARB therapy not prescribed during the measurement period, reason not given*:

- a. If *ACE inhibitor or ARB therapy not prescribed during the measurement period, reason not given* equals Yes, include in *Data Completeness Not Met and Performance Not Met*.
 - *Data Completeness Met and Performance Not Met* letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 patients in the Sample Calculation.
- b. If *ACE inhibitor or ARB therapy not prescribed during the measurement period, reason not given* equals No, proceed to check *Data Completeness Not Met*.

13. Check *Data Completeness Not Met*:

- If *Data Completeness Not Met*, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

Sample Calculations

Data Completeness equals Performance Met (a equals 40 patients) plus Denominator Exception ($b^1 + b^2 = 10$ patients) plus Performance Not Met (c equals 20 patients) divided by Eligible Population / Denominator (d equals 80 patients). All equals 70 patients divided by 80 patients. All equals 87.50 percent.

Performance Rate equals Performance Met (a equals 40 patients) divided by Data Completeness Numerator (70 patients) minus Denominator Exception ($b^1 + b^2 = 10$ patients). All equals 40 patients divided by 60 patients. All equals 66.67 percent.

*See the posted measure specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient-Process

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.